IPO registrations (S-1, F-1) · Registrants
NeuBase Therapeutics, Inc.
- SEC CIK
- 1173281 · filings on EDGAR ↗
- Former names
- Ohr Pharmaceutical Inc (2009–2019); BBM HOLDINGS, INC. (2007–2009); PRIME RESOURCE INC (2002–2007)
- Registration
- Form S-1, first filed 2023-07-28; 1 initial registration, 0 amendments
- Outcome
- Declared effective 2023-08-10
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 350 TECHNOLOGY DRIVE, Pittsburgh, PA 15219
- EIN
- 46-5622433
- EDGAR entity type
- operating
- Insiders and CEO pay
- NeuBase Therapeutics, Inc. on the corporate pages
Offering terms
- Shares offered
- 5,394,068
- Listing
- Nasdaq under the symbol NBSE
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: NEUBASE THERAPEUTICS INC EXACT (EIN (EXACT))
- Form D issuer: NeuBase Therapeutics, Inc. EXACT (CIK (EXACT))
- SEC filer: NeuBase Therapeutics, Inc. EXACT (CIK (EXACT))
Filings 4
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2023-07-28 | S-1 | S-1 (registration) | NeuBase Therapeutics, Inc. | 0001104659-23-084932 ↗ |
| 2023-08-10 | EFFECT | EFFECT (declared effective) | NeuBase Therapeutics, Inc. | 9999999995-23-002343 ↗ |
| 2024-07-02 | EFFECT | EFFECT (declared effective) | NeuBase Therapeutics, Inc. | 9999999995-24-002048 ↗ |
| 2024-07-02 | EFFECT | EFFECT (declared effective) | NeuBase Therapeutics, Inc. | 9999999995-24-002049 ↗ |
Prospectus pages read 1
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023-07-28 | S-1 | registration statement | $2.57 | 5,394,068 | $13,862,754 | Nasdaq NBSE | 0 | primary document; price sentence, shares headline, proceeds computed | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Almenoff June Sherie | Director | 8 | 2013–2017 | ||
| Backenroth Samuel | Officer | CEO & VP of Bus. Development; CFO, Treasurer & Secretary; CFO & VP of Bus. Development; Chief Financial Officer | 12 | 2013–2020 | |
| GREENSTEIN IRA A | Director; Director,Officer | Chairman of the Board | 8 | 2013–2016 | |
| Taraporewala Irach B. | Director,Officer; Officer | CEO & President; Chief Executive Officer | 4 | 2013–2015 | |
| Riedhammer Thomas M | Director | 6 | 2013–2017 | ||
| HIRSCHMAN ORIN | Director; Director,TenPercentOwner | 8 | 2013–2017 | ||
| Slakter Jason Scott | Director; Director,Officer | Chief Executive Officer | 18 | 2015–2017 | |
| Ingerman Avner | Officer | Chief Clinical Officer | 1 | 2015 | |
| Ferguson Michael | Director | 3 | 2017 | ||
| GOLDSTEIN DOV A MD | Director | 8 | 2019–2022 | ||
| Miralles Gines Diego | Director | 3 | 2019–2020 | ||
| PRENDERGAST FRANKLYN G | Director | 5 | 2019–2022 | ||
| RICHMAN ERIC I | Director | 8 | 2019–2022 | ||
| Stephan Dietrich A | Director,Officer; Director,Officer,TenPercentOwner | CEO; CEO and Director; Founder and CEO; President and CEO | 13 | 2019–2023 | |
| Lipizzaner LLC | TenPercentOwner | 3 | 2020 | ||
| Mann William Roland | Officer | Chief Operating Officer; COO | 6 | 2020–2022 | |
| Bradshaw Curt | Officer | Chief Scientific Officer | 2 | 2020 | |
| McDougall Gerald J | Director | 4 | 2021–2022 | ||
| Motesharei Kianoush | Officer | See Remarks | 2 | 2021 | |
| Rojas-Caro Sandra | Officer | Chief Medical Officer | 3 | 2021–2022 | |
| Ende Eric J | Director | 3 | 2022 | ||
| Branning Todd P. | Officer | Chief Financial Officer | 6 | 2022–2023 | |
| Symetryx Corp | Other; TenPercentOwner | 6 | 2023 | ||
| Shiff Aleta | Other; TenPercentOwner | 2 | 2023 | ||
| Shiff Barry | Other; TenPercentOwner | 2 | 2023 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2023-07-07 | NeuBase Therapeutics, Inc. | Biotechnology | $5,000,002 | $5,000,002 | 1 | 1 |
| 2014-12-29 | Ohr Pharmaceutical Inc | Biotechnology | $50,000 | $50,000 | 1 | 1 |
| 2014-06-04 | Ohr Pharmaceutical Inc | Biotechnology | $25,180,224 | $10,180,224 | 1 | 1 |
| 2014-01-16 | Ohr Pharmaceutical Inc | Biotechnology | $569,581 | $569,581 | 3 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | NEUBASE THERAPEUTICS INC | PA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | NeuBase Therapeutics, Inc. | PA | Form D private offerings | CIK (EXACT) |
| Patent assignee | NEUBASE THERAPEUTICS, INC. | PA | Patents (USPTO) | name and state |
| SEC filer | NeuBase Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | NEUBASE THERAPEUTICS INC | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, PA first:
- COLLAGENEX PHARMACEUTICALS INC PA
- ORAPHARMA INC PA
- VICURON PHARMACEUTICALS INC PA
- INOVIO PHARMACEUTICALS, INC. PA
- ADOLOR CORP PA
- PROTARGA INC PA
- Traws Pharma, Inc. PA
- MADRIGAL PHARMACEUTICALS, INC. PA
- Vitae Pharmaceuticals, Inc PA
- PhaseBio Pharmaceuticals Inc PA
In other datasets, the same topic (Health) in PA:
- Nonprofit: 445 FOUNDATION (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health